| dc.contributor |
Epicentre, Paris, France. |
|
| dc.creator |
Guthmann, J P |
|
| dc.creator |
Pittet, A |
|
| dc.creator |
Lesage, A |
|
| dc.creator |
Imwong, M |
|
| dc.creator |
Lindegardh, N |
|
| dc.creator |
Min Lwin, M |
|
| dc.creator |
Zaw, T |
|
| dc.creator |
Annerberg, A |
|
| dc.creator |
de Radiguès, X |
|
| dc.creator |
Nosten, F |
|
| dc.date |
2008-01 |
|
| dc.date.accessioned |
2017-01-31T07:10:49Z |
|
| dc.date.available |
2017-01-31T07:10:49Z |
|
| dc.identifier |
Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. 2008, 13 (1):91-8 Trop. Med. Int. Health |
|
| dc.identifier |
1365-3156 |
|
| dc.identifier |
18291007 |
|
| dc.identifier |
10.1111/j.1365-3156.2007.01978.x |
|
| dc.identifier |
http://hdl.handle.net/10144/26152 |
|
| dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/26152 |
|
| dc.identifier |
Tropical Medicine & International Health |
|
| dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/26152 |
|
| dc.description |
OBJECTIVE: To assess the efficacy of chloroquine in the treatment of Plasmodium vivax malaria in in Dawei District, southern Myanmar. METHODS: Enrolled patients at Sonsinphya clinic >6 months of age were assessed clinically and parasitologically every week for 28 days. To differentiate new infections from recrudescence, we genotyped pre- and post-treatment parasitaemia. Blood chloroquine was measured to confirm resistant strains. RESULTS: Between December 2002 and April 2003, 2661 patients were screened, of whom 252 were included and 235 analysed. Thirty-four per cent (95% CI: 28.1-40.6) of patients had recurrent parasitaemia and were considered treatment failures. 59.4% of these recurrences were with a different parasite strain. Two (0.8%) patients with recurrences on day 14 had chloroquine concentrations above the threshold of 100 ng/ml and were considered infected with chloroquine resistant parasites. 21% of failures occurred during the first 3 weeks of follow-up: early recurrence and median levels of blood chloroquine comparable to those of controls suggested P. vivax resistance. CONCLUSIONS: Plasmodium vivax resistance to chloroquine seems to be emerging in Dawei, near the Thai-Burmese border. While chloroquine remains the first-line drug for P. vivax infections in this area of Myanmar, regular monitoring is needed to detect further development of parasite resistance. |
|
| dc.language |
en |
|
| dc.publisher |
Wiley-Blackwell |
|
| dc.rights |
Archived on this site with the kind permission of Wiley-Blackwell, [url]http://www.blackwell-synergy.com/loi/tmi[/url] |
|
| dc.title |
Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. |
|